About
Small Molecules, Monoclonal Antibodies
Areas of Focus
Categories
Small Molecule PharmaceuticalSouthwestern U.S.
Team (17)
Angélique Bordey, PhD
SVP, Neuroscience
Cassava Sciences
team_member
Claude Nicaise, M.D.
Chair of the Compensation CommitteeMember of the Nominating and Governance Committee
Cassava Sciences
board_chair
Eric Schoen
Chief Financial Officer
Cassava Sciences
executive
Freda Nassif
Chief Business Officer
Cassava Sciences
team_member
George (Ben) Thornton PhD
Sr. VP, Technology
Cassava Sciences
executive
Jack Moore, PhD
Sr. VP, Clinical Development
Cassava Sciences
executive
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
9
As Collaborator
0
Total Enrollment
3,443
By Phase
PHASE1: 3PHASE3: 3PHASE2: 3
By Status
COMPLETED: 6TERMINATED: 3
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT06390410Lead Sponsor
A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function
PHASE1Completed
27 participants
Started: Jun 26, 2024 · Completed: Dec 7, 2024
NCT06195319Lead Sponsor
Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects
PHASE1Completed
8 participants
Started: Feb 7, 2024 · Completed: Mar 27, 2024
NCT05575076Lead Sponsor
Open-label Extension for Phase 3 Clinical Trials of Simufilam
PHASE3Terminated
1,081 participants
Started: Nov 7, 2022 · Completed: Jan 31, 2025
NCT05352763Lead Sponsor
Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease
PHASE2Terminated
90 participants
Started: May 12, 2022 · Completed: Dec 31, 2024
NCT05026177Lead Sponsor
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
PHASE3Terminated
1,125 participants
Started: Nov 18, 2021 · Completed: Dec 30, 2024
Locations (1)
Headquarters
Austin, TX, United States
Map
Loading map...